Source: Annual Congress 2006 - Epidemiology and treatment of tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
T. A. Alexandrina, S. S. Cherenko (Kiev, Ukraine). Timing of concurrent highly active antiretroviral therapy (HAART) in adults with tuberculosis. Eur Respir J 2006; 28: Suppl. 50, 1746

Member's Comments

No comment yet.

Related content which might interest you: Quality of sleep and psychiatric parameters in patients with HIV infection on highly active antiretroviral therapy (HAART) Source: Annual Congress 2009 - Clinical aspects of sleep apnoea Year: 2009 Bronchoscopy yield in HIV positive patients, ten years on from the introduction of highly active anti-retroviral therapy Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections Year: 2009 Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004 Current antiretroviral therapy Source: Eur Respir Monogr 2014; 66: 12-25 Year: 2014 Unmasking tuberculosis in the era of antiretroviral treatment Source: Eur Respir J 2012; 39: 1064-1075 Year: 2012 Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019 The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003 Impact of HIV status, CD4 count and antiretroviral treatment on tuberculosis treatment outcomes in a low-burden country Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 IP-10 decreases during antituberculous treatment in children with active tuberculosis. Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with advanced HIV disease Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 What happens to pneumocystis prophylaxis use when antiretroviral therapy is widely available? Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 Improvement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapy Source: Eur Respir J 2009; 34: 277-278 Year: 2009 Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 HIV-associated disruption of lung cytokine networks is incompletely restored in asymptomatic HIV-infected Malawian adults on antiretroviral therapy Source: ERJ Open Res, 3 (4) 00097-2017; 10.1183/23120541.00097-2017 Year: 2017 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Use of shortened chemotherapy regimens in treatment of adolescents with MDR/XDR TB Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018